¸Å³â 1000°Ç ÀÌ»ó À¯¹æ¾Ï ¼ö¼ú ÁøÇà
| Á¦ ¸ñ | ÀÌÁ¨ µÎ·ÆÁö ¾Ê´Ù! À¯¹æ¾Ï |
|---|---|
| ÃâÆÇ»ç | ÀÌÁ¨¹Ìµð¾î |
| ¹ßÇàÀÏ | 2009³â |
| Á¦ ¸ñ | À¯¹æÇÐ |
|---|---|
| ÃâÆÇ»ç | ÀÏÁ¶°¢ |
| ¹ßÇàÀÏ | 2005³â |
| Á¦ ¸ñ | À¯¹æ¾Ï |
|---|---|
| ÃâÆÇ»ç | ¾ÆÄ«µ¥¹Ì¾Æ |
| ¹ßÇàÀÏ | 2005³â |
| Á¦ ¸ñ | Circulation Time-Optimized Albumin Nanoplatform for Quantitative Visualization of Lung Metastasis via Targeting of Macrophages |
|---|---|
| ¹ßÇ¥³âµµ | 2022-8 |
| ¹ßÇ¥Áö | ACS NANO |
| Á¦ ¸ñ | Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF-beta pathway (Jan, 10.1038/s41417-021-00419-0, 2022) |
|---|---|
| ¹ßÇ¥³âµµ | 2022-8 |
| ¹ßÇ¥Áö | CANCER GENE THERAPY |
| Á¦ ¸ñ | Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapy |
|---|---|
| ¹ßÇ¥³âµµ | 2022-8 |
| ¹ßÇ¥Áö | BREAST CANCER RESEARCH AND TREATMENT |
| Á¦ ¸ñ | Á¦¸ñ A nomogram for predicting three or more axillary lymph node involvement before breast cancer surgery |
|---|---|
| ¹ßÇ¥³âµµ | 2022-7 |
| ¹ßÇ¥Áö | SCIENTIFIC REPORTS |
| Á¦ ¸ñ | Transcriptome analysis of SerpinB2-deficient breast tumors provides insight into deciphering SerpinB2-mediated roles in breast cancer progression |
|---|---|
| ¹ßÇ¥³âµµ | 2022-6 |
| ¹ßÇ¥Áö | BMC GENOMICS |
| Á¦ ¸ñ | Reduced miR-371b-5p expression drives tumor progression via CSDE1/RAC1 regulation in triple-negative breast cancer |
|---|---|
| ¹ßÇ¥³âµµ | 2022-5 |
| ¹ßÇ¥Áö | ONCOGENE |
| Á¦ ¸ñ | Spatial epitranscriptomics reveals A-to-I editome specific to cancer stem cell microniches |
|---|---|
| ¹ßÇ¥³âµµ | 2022-5 |
| ¹ßÇ¥Áö | NATURE COMMUNICATIONS |

¼¿ï´ëº´¿øÀº º»¿øÀ» ºñ·ÔÇÑ ¾î¸°À̺´¿ø, ¾Ïº´¿ø, ÀÇ»ý¸í¿¬±¸¿øÀ¸·Î ±¸¼ºµÅ ÀÖ´Â Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î 1786º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 540¿© ¸íÀÇ ±³¼ö¿Í 5400¿© ¸íÀÇ Á÷¿øÀÌ ÇÏ·ç Æò±Õ 1700¿© ¸íÀÇ ÀÔ¿øÈ¯ÀÚ¿Í 8600¸íÀÌ ³Ñ´Â ¿Ü·¡È¯ÀÚ¸¦ µ¹º¸°í ÀÖ´Ù. ¼¼°èÀû ÷´Ü Áø·á ¿µ¿ªÀ» Áö¼ÓÀûÀ¸·Î È®º¸ÇÔÀ¸·Î½á ÃÖ»óÀÇ Áø·á ¼ºñ½º¸¦ Á¦°øÇϰí, ¿ì¸®³ª¶ó ÀÇ·á ¼±ÁøÈ¸¦ Ãß±¸ÇÏ´Â Á¤Ã¥ Çù·Â º´¿øÀÌ´Ù.
¼¿ïƯº°½Ã Á¾·Î±¸ ´ëÇзΠ101